دورية أكاديمية

1155. Short vs. Long Symptom Duration Prior to Remdesivir for Hospitalized Patients with COVID-19

التفاصيل البيبلوغرافية
العنوان: 1155. Short vs. Long Symptom Duration Prior to Remdesivir for Hospitalized Patients with COVID-19
المؤلفون: Elshaboury, Ramy H, Adamsick, Meagan L, Huang, Joanne, Winkler, Marisa, Ghebremichael, Musie, Cheung, Fiona, Polsonetti, Bryan, Mozaffari, Essy, Chen, Linda, Juelg, Boris, Hohmann, Elizabeth
المصدر: Open Forum Infectious Diseases ; volume 9, issue Supplement_2 ; ISSN 2328-8957
بيانات النشر: Oxford University Press (OUP)
سنة النشر: 2022
مصطلحات موضوعية: Infectious Diseases, Oncology
الوصف: Background Remdesivir (RDV) has been a mainstay of COVID-19 therapy for hospitalized patients. Impact of RDV timing in relationship to symptom-onset in hospitalized patients remains unclear, though early treatment is theorized to improve antiviral activity and clinical outcomes. Methods This was a single-center retrospective study of adult patients hospitalized for severe COVID-19 treated with RDV. Patient charts were reviewed by 2 independent investigators to determine disease course and outcomes. Patients were stratified based on time from symptom-onset to RDV (short: ≤7 vs. long: >7 days). The primary outcome was time to clinical recovery within 28 days. Secondary outcomes were proportion of patients recovered and proportion discharged from the hospital within 10, 14, and 28 days; and mortality within 28 days. Time to recovery was analyzed using the Kaplan-Meier method and the significance was tested by log rank tests. Cox’s proportional hazards models were used to estimate hazard ratios (HR). Fisher’s exact test was used to compare recovery rates between groups. Results Overall, 405 patient charts were reviewed, and 337 met the inclusion criteria. On the first day of RDV, 178 (53%) of patients had symptoms for <7 days, while 159 (47%) of patients had symptoms for >7 days. Patients in the short symptom duration group were slightly older (66.5 vs. 59 years, p=0.004) and had more co-morbidities. Median time to recovery was 7 (95% CI 5-9) in the short- vs. 5 (95% CI 4-6) days in the long-symptom duration groups, respectively, p=0.066. By day 10, 111 (62%) vs. 116 (73%) patients met the clinical recovery definition (p=0.048), and 113 (63%) vs. 119 (75%) patients were discharged from the hospital (p=0.026) in the short- vs. long-symptom duration groups, respectively. In the Cox’s proportional hazards model, age, disease severity, and co-morbidities (kidney, liver, chronic respiratory diseases, and type II diabetes mellitus) were associated with longer recovery times. Conclusion In ...
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1093/ofid/ofac492.993
الإتاحة: https://doi.org/10.1093/ofid/ofac492.993Test
https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.993/47892525/ofac492.993.pdfTest
حقوق: https://creativecommons.org/licenses/by/4.0Test/
رقم الانضمام: edsbas.C3B31B8
قاعدة البيانات: BASE